Sivahari Prasad Gorantla

Oncogenic JAK2 ^V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Alessandro Prestipino, Alica Joana Emhardt, Konrad Aumann et al. · Science Translational Medicine · 2018 · 218 citations · Full text

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Christoph Rummelt, Sivahari Prasad Gorantla, Manja Meggendorfer et al. · Leukemia · 2020 · 45 citations

Flt3 Kinase Inhibitors, Jak-mutations Confer Resistance, Signal Transduction +10

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia

Chuanjiang Yu, Sivahari Prasad Gorantla, Alina Müller-Rudorf et al. · Haematologica · 2019 · 35 citations · Full text

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

Nikolas von Bubnoff, Sivahari Prasad Gorantla, Richard A. Engh et al. · Oncogene · 2010 · 32 citations

Hematological Malignancy, Clinical Resistance, Pdgfr Inhibitors +8

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice

Sivahari Prasad Gorantla, Tobias Dechow, Rebekka Grundler et al. · Blood · 2010 · 27 citations · Full text